Adenomatous polyposis coli

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on:

Wednesday, April 24, 2024

Decentralized finance, FDA, Cancer, Mutation, Safety, NDA, Plantar fibromatosis, Food, Nirogacestat, MEK, ASCO, Patient, Society, APC, Adenomatous polyposis coli, Annual general meeting, Therapy, Pharmaceutical industry

STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024. SpringWorks recently initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib in pediatric and adult patients with NF1-PN.

Key Points:

STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024.
SpringWorks recently initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib in pediatric and adult patients with NF1-PN.
Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors were also accepted for presentation at ASCO, including an abstract describing the onset and resolution of ovarian toxicity for desmoid tumor patients treated with nirogacestat, as well as two additional sub-group analyses evaluating nirogacestat in desmoid tumor patients with poor prognostic factors and in those with adenomatous polyposis coli (APC) mutations.
“The Phase 2b ReNeu trial data are the cornerstone of our NDA for mirdametinib in NF1-PN, and we are very pleased that these data were accepted for an oral presentation at ASCO,” said Jim Cassidy, M.D., Ph.D., Chief Medical Officer of SpringWorks.

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

Retrieved on:

Monday, November 1, 2021

The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.

Key Points:

The E7386 targets, beta-catenin, is considered to be one of the undruggable targets that are particularly difficult to develop into drug discovery.
E7386 is a CBP / beta-catenin inhibitor that inhibits CBP and beta-catenin protein-protein interactions and regulates the Wnt signal-dependent gene expression.
(1)
Based on the POC achievement, Eisai has initiated a phase Ib/II clinical trial (Study 201) of E7386 in combination with anti-PD-1 therapy pembrolizumab for solid tumors in Japan.
E7386 is a CBP / beta-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and beta-catenin, and regulates the Wnt signaling-dependent gene expression.

Linesight's Giles Heather named RICS Young Surveyor of the Year 2020

Retrieved on:

Wednesday, December 2, 2020

Other Construction & Property, Construction & Property, Professional services, Finance, Real estate, Fictional characters, Real estate valuation, Home inspection, Construction, Housing in the United Kingdom, Royal Institution of Chartered Surveyors, Quantity surveyor, Rupert Giles, Giles, Adenomatous polyposis coli

Leading international construction consultancy, Linesight , is delighted to announce that Giles Heather , an Associate Director based in its London office, was named the RICS - Matrics Young Surveyor of the Year 2020 at the virtual ceremony that took place on Friday, 27th November.

Key Points:

Leading international construction consultancy, Linesight , is delighted to announce that Giles Heather , an Associate Director based in its London office, was named the RICS - Matrics Young Surveyor of the Year 2020 at the virtual ceremony that took place on Friday, 27th November.
Giles also triumphed in the Quantity Surveying and Construction category earlier in the evening.
In 2020 Giles and his team launched a Wellbeing initiative to ensure that their organisations employees were treated as individuals and were offered support in their health and wellbeing.
As an APC Lead, Giles offers guidance and support to his colleagues involved in the APC, helping his organisation achieve a 100% APC pass rate.

Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs

Retrieved on:

Monday, September 23, 2019

Branches of biology, Tumor suppressor genes, Adenomatous polyposis coli, Signal transduction, Biology, Catenins, Genes

We are excited to bring both of these important programs aimed at difficult-to-treat genetically-defined cancers into our portfolio.

Key Points:

We are excited to bring both of these important programs aimed at difficult-to-treat genetically-defined cancers into our portfolio.
We are enthusiastic about the opportunity to develop PDE10 inhibition to target the Wnt/APC/-catenin pathway where it is an oncogenic driver.
Under the terms of the collaboration and license agreement, Anchiano will be granted an exclusive option to license the RAS and PDE10/-catenin inhibitors in exchange for a $3 million upfront payment to ADT and will fund certain research activities.
If Anchiano exercises its option, it will be responsible for development and commercialization and will incur additional payment obligations, including milestone and royalty payments to ADT.

Argan, Inc. Reports First Quarter Results

Retrieved on:

Monday, June 10, 2019

Energy, Oil, Gas, Manufacturing, Engineering, Natural Resources, Other Natural Resources, Professional services, Consulting, Construction & Property, Commercial Building & Real Estate, Adenomatous polyposis coli, Impairment

This loss was fully recognized in our operating results for the three-month period ended April 30, 2019.

Key Points:

This loss was fully recognized in our operating results for the three-month period ended April 30, 2019.
Due to the limited revenues during the quarter and the loss project at APC, we are reporting a negative gross loss and gross loss percentage for the quarter, compared to gross profit in the prior year quarter.
Due to loss at APC mentioned above, the Company recorded a $2.1 million impairment charge on its goodwill for APC during the current quarter.
Commenting on Argans results, Rainer Bosselmann, Chairman and Chief Executive Officer, stated, We are disappointed with our results for the quarter, especially as it relates to the loss we recorded on our APC project in the United Kingdom.

Schneider Electric Announces APC NetShelter Racks and Micro Data Centers Achieve Cisco Certification

Retrieved on:

Thursday, October 25, 2018

Computing, Information and communications technology, Data centers, Technology, Schneider Electric, Micro Data Center, Cisco Systems, APC, Converged infrastructure, Adenomatous polyposis coli

With the certification, all of these converged infrastructures can ship in APC NetShelter SX racks with Shock Packaging.

Key Points:

With the certification, all of these converged infrastructures can ship in APC NetShelter SX racks with Shock Packaging.
"APC by Schneider was the perfect company to partner with in the Micro Data Center solutions space," said Dan Hanson, Senior Director, UCS Product Management, Cisco.
Check out the APC alliances page to learn more about how APC and Cisco are working together to create solutions that power advanced data center technologies.
Schneider Electric is leading the Digital Transformation of Energy Management and Automation in Homes, Buildings, Data Centers, Infrastructure and Industries.

Schneider Electric Announces APC NetShelter Racks and Micro Data Centers Achieve Cisco Certification

Retrieved on:

Wednesday, October 24, 2018

Computing, Information and communications technology, Data centers, Technology, Schneider Electric, Micro Data Center, Cisco Systems, APC, Converged infrastructure, Adenomatous polyposis coli

With the certification, all of these converged infrastructures can ship in APC NetShelter SX racks with Shock Packaging.

Key Points:

With the certification, all of these converged infrastructures can ship in APC NetShelter SX racks with Shock Packaging.
"APC by Schneider was the perfect company to partner with in the Micro Data Center solutions space," said Dan Hanson, Senior Director, UCS Product Management, Cisco.
Check out the APC alliances page to learn more about how APC and Cisco are working together to create solutions that power advanced data center technologies.
Schneider Electric is leading the Digital Transformation of Energy Management and Automation in Homes, Buildings, Data Centers, Infrastructure and Industries.